ArticleCancer science2026
Tumor-Derived Prostaglandin E2 Promotes Colorectal Cancer Progression by Inducing N2-Type TAN Polarization.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Tumor-associated neutrophils (TANs) play crucial roles in malignant tumors, and their polarization is considered a determining factor in cancer progression. However, knowledge concerning the molecular mechanisms that regulate the changes in the polarization phenotype of TANs and their impact on tumor biology is limited. Here, we demonstrate that tumor-derived prostaglandin E2 (PGE2) regulates the polarization of TANs toward the N2 phenotype within the tumor microenvironment, promoting tumor cell proliferation and migration. Mechanistically, PGE2 is released from the LDs of CRC cells into the TME, where the stimulation of ROS-mediated methylation increases through binding with the surface receptors prostaglandin E receptor 2 (EP2, PTGER2) and EP4 on TANs, resulting in a reduction in the expression of the transcriptional repressor FOXO3a and thereby eliminating its ability to bind to the promoter region of N2-associated molecules such as ARG1, MMP9, and BV8 in TANs and promote their production. In summary, PGE2-induced N2-type TAN polarization directly affects the malignant progression of tumors. Our research revealed that PGE2 could be a potential effective molecule for targeting TANs in antitumor immunotherapy for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.